封锁
免疫检查点
T细胞
抑制器
免疫系统
免疫疗法
癌症研究
免疫学
生物
医学
癌症
受体
遗传学
生物化学
标识
DOI:10.1158/2326-6066.cir-22-0708
摘要
Abstract Defining the mechanisms of action of immune checkpoint blockade therapies is essential for effectively designing combination therapeutic approaches and developing the next generation of immunotherapies. In this issue, Schaafsma and colleagues report that V-domain immunoglobulin suppressor of T-cell activation antagonism acts through mechanisms distinct from anti–CTLA-4 and anti—programmed cell death protein 1 via remodeling of the myeloid-cell compartment and modulating T-cell quiescence. See related article by Schaafsma et al. p. 38 (1).
科研通智能强力驱动
Strongly Powered by AbleSci AI